Coukos, George

Publications

Sort by

Co-Author Network

selected publications

Cancer immunotherapy insights: key takeaways from the ADSCC bone marrow and cellular therapy congress 2024. Frontiers in immunology. 2026 Review GET IT
The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee. Journal for immunotherapy of cancer. 2025 Review GET IT
Times cited: 1
Multi-modal image analysis for large-scale cancer tissue studies within IMMUcan. Cell reports methods. 2025 Academic Article GET IT
Immune correlates and mechanisms of TIL therapy efficacy: current insights and knowledge gaps. Trends in cancer. 2025 Review GET IT
Times cited: 6
Highly efficient gene knockout in tumor-infiltrating lymphocytes by adenine base editing. Molecular therapy. Oncology. 2025 Academic Article GET IT
Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer. Cancer cell. 2025 Academic Article GET IT
Times cited: 8
Engineered CD4 TCR T cells with conserved high-affinity TCRs targeting NY-ESO-1 for advanced cellular therapies in cancer. Science advances. 2025 Academic Article GET IT
Times cited: 2
Tumour-associated vasculature in T cell homing and immunity: opportunities for cancer therapy. Nature reviews. Immunology. 2025 Review GET IT
Times cited: 11
Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II Study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025 Academic Article GET IT
Times cited: 5
Age-associated nicotinamide adenine dinucleotide decline drives CAR-T cell failure. Nature cancer. 2025 Academic Article GET IT
Times cited: 16
Transcriptome analysis of archived tumors by Visium, GeoMx DSP, and Chromium reveals patient heterogeneity. Nature communications. 2025 Academic Article GET IT
Times cited: 1
Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Annals of oncology : official journal of the European Society for Medical Oncology. 2025 Review GET IT
Times cited: 3
Enrichment of CD7⁺CXCR3⁺ CAR T-cells in infusion products is associated with durable remission in relapsed or refractory diffuse large B-cell lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2025 Academic Article GET IT
Times cited: 3
T cell receptor precision editing of regulatory T cells for celiac disease. Science translational medicine. 2025 Academic Article GET IT
Times cited: 3
Potent and durable control of mesothelin-expressing tumors by a novel T cell-secreted bi-specific engager. Journal for immunotherapy of cancer. 2025 Academic Article GET IT
Times cited: 2
Author Correction: Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithms. 2025 GET IT
Times cited: 1
DNA-dependent protein kinase inhibitors PI-103 and samotolisib augment CRISPR/Cas9 knock-in efficiency in human T cells. Cytotherapy. 2025 Academic Article GET IT
Times cited: 1
Novel strategies to manage CAR-T cell toxicity. Nature reviews. Drug discovery. 2025 Review GET IT
Times cited: 32
Art of TIL immunotherapy: SITC's perspective on demystifying a complex treatment. Journal for immunotherapy of cancer. 2025 Review GET IT
Times cited: 11
Cancer cells impair monocyte-mediated T cell stimulation to evade immunity. Nature. 2024 Academic Article GET IT
Times cited: 72
A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy. Nature biotechnology. 2024 Academic Article GET IT
Times cited: 47
Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma. Immunity. 2024 Academic Article GET IT
Times cited: 23
Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach. Nature reviews. Clinical oncology. 2024 Review GET IT
Times cited: 55
Predicting Antigen-Specificities of Orphan T Cell Receptors from Cancer Patients with TCRpcDist. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2024 Academic Article GET IT
Times cited: 5
Probing the killing potency of tumor-infiltrating lymphocytes on microarrayed colorectal cancer tumoroids. NPJ precision oncology. 2024 Academic Article GET IT
Times cited: 3
Lung Cancer Adoptive Cell Therapy: Inspiring TIL ACT Comes Center Stage. Cancer discovery. 2024 Academic Article GET IT
Times cited: 4
Reflections on the opportunities and challenges of applying experience-based co-design (EBCD) to phase 1 clinical trials in oncology. Health expectations : an international journal of public participation in health care and health policy. 2024 Academic Article GET IT
Times cited: 2
Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis. Annals of oncology : official journal of the European Society for Medical Oncology. 2024 Review GET IT
Times cited: 30
Patient-derived mini-colons enable long-term modeling of tumor-microenvironment complexity. Nature biotechnology. 2024 Academic Article GET IT
Times cited: 45
Nanoplasmonic Single-Tumoroid Microarray for Real-Time Secretion Analysis. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2024 Academic Article GET IT
Times cited: 12
Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithms. Nature biotechnology. 2024 Academic Article GET IT
Times cited: 20
Urolithin-A Promotes CD8+ T Cell-mediated Cancer Immunosurveillance via FOXO1 Activation. Cancer research communications. 2024 Academic Article GET IT
Times cited: 14
PGE₂ inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function. Nature. 2024 Academic Article GET IT
Times cited: 136
Combining SiRPα decoy-coengineered T cells and antibodies augments macrophage-mediated phagocytosis of tumor cells. The Journal of clinical investigation. 2024 Academic Article GET IT
Times cited: 6
Editor's Note: In Vivo Persistence, Tumor Localization, and Antitumor Activity of CAR-Engineered T Cells Is Enhanced by Costimulatory Signaling through CD137 (4-1BB). 2024 GET IT
Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8⁺ T-myeloid cell networks in melanoma. Science immunology. 2024 Academic Article GET IT
Times cited: 53
Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00. European journal of cancer. 2024 Academic Article GET IT
Times cited: 3
Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient. 2023 GET IT
Times cited: 2
B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2023 Academic Article GET IT
Times cited: 38
Machine learning methods and harmonized datasets improve immunogenic neoantigen prediction. Immunity. 2023 Academic Article GET IT
Times cited: 59
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma. Journal for immunotherapy of cancer. 2023 Academic Article GET IT
Times cited: 10
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer. Nature cancer. 2023 Academic Article GET IT
Times cited: 23
Activation of the transcription factor NFAT5 in the tumor microenvironment enforces CD8⁺ T cell exhaustion. Nature immunology. 2023 Academic Article GET IT
Times cited: 39
Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors. Nature communications. 2023 Academic Article GET IT
Times cited: 49
The immunopeptidome landscape associated with T cell infiltration, inflammation and immune editing in lung cancer. Nature cancer. 2023 Academic Article GET IT
Times cited: 58
TCR sequencing and cloning methods for repertoire analysis and isolation of tumor-reactive TCRs. Cell reports methods. 2023 Academic Article GET IT
Times cited: 40
Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8⁺ T cells. Nature immunology. 2023 Academic Article GET IT
Times cited: 36
A lentiviral vector for the production of T cells with an inducible transgene and a constitutively expressed tumour-targeting receptor. Nature biomedical engineering. 2023 Academic Article GET IT
Times cited: 18
Machine learning predictions of MHC-II specificities reveal alternative binding mode of class II epitopes. Immunity. 2023 Academic Article GET IT
Times cited: 73
Towards next-generation TIL therapy: TILs enriched in neoepitope-specific T cells. Clinical and translational medicine. 2023 Academic Article GET IT
TIL Therapy Entering the Mainstream. The New England journal of medicine. 2022 Editorial Article GET IT
Times cited: 15
Genetics and anatomy sculpt immune-cell partners of ovarian cancer. Nature. 2022 Comment GET IT
Times cited: 3
IL-2 engineered MSCs rescue T cells in tumours. Nature cell biology. 2022 Comment GET IT
Times cited: 1
Patient-reported outcomes in adoptive cell-therapy trials: mind the gap. Journal for immunotherapy of cancer. 2022 Academic Article GET IT
Times cited: 2
Structure-based optimization of type III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors. Journal of enzyme inhibition and medicinal chemistry. 2022 Academic Article GET IT
Times cited: 4
A bioluminescent-based probe for in vivo non-invasive monitoring of nicotinamide riboside uptake reveals a link between metastasis and NAD⁺ metabolism. Biosensors & bioelectronics. 2022 Academic Article GET IT
Times cited: 29
Enforcing GLUT3 expression in CD8⁺ T cells improves fitness and tumor control by promoting glucose uptake and energy storage. Frontiers in immunology. 2022 Academic Article GET IT
Times cited: 35
Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation. Nature reviews. Cancer. 2022 Review GET IT
Times cited: 131
CAR T cells targeting the ganglioside NGcGM3 control ovarian tumors in the absence of toxicity against healthy tissues. Frontiers in immunology. 2022 Academic Article GET IT
Times cited: 14
Low-dose irradiation for reversing immunotherapy resistance: how to translate?. Journal for immunotherapy of cancer. 2022 Editorial Article GET IT
Times cited: 22
Trabectedin and Durvalumab Combination Is Feasible and Active in Relapsing Ovarian Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Editorial Article GET IT
Times cited: 6
Deciphering the landscape of phosphorylated HLA-II ligands. iScience. 2022 Academic Article GET IT
Times cited: 4
Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC. The Lancet. Oncology. 2022 Letter GET IT
Times cited: 5
Lighting up the tumor fire with low-dose irradiation. Trends in immunology. 2022 Review GET IT
Times cited: 53
A cell-based phenotypic library selection and screening approach for the de novo discovery of novel functional chimeric antigen receptors. Scientific reports. 2022 Academic Article GET IT
Times cited: 8
A roadmap for driving CAR T cells toward the oncogenic immunopeptidome. Cancer cell. 2022 Comment GET IT
Times cited: 8
High-Throughput Single-Cell TCR-pMHC Dissociation Rate Measurements Performed by an Autonomous Microfluidic Cellular Processing Unit. ACS sensors. 2022 Academic Article GET IT
Times cited: 1
Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma. Journal for immunotherapy of cancer. 2022 Academic Article GET IT
Times cited: 28
TEM1-targeting PEGylated PLGA shikonin nanoformulation for immunomodulation and eradication of ovarian cancer. BioImpacts : BI. 2021 Academic Article GET IT
Times cited: 11
Sensitive identification of neoantigens and cognate TCRs in human solid tumors. Nature biotechnology. 2021 Academic Article GET IT
Times cited: 79
Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope. Nature communications. 2021 Academic Article GET IT
Times cited: 22
Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. Cancer cell. 2021 Academic Article GET IT
Times cited: 123
Identification of tumor antigens with immunopeptidomics. Nature biotechnology. 2021 Review GET IT
Times cited: 175
Microfluidic Device for Droplet Pairing by Combining Droplet Railing and Floating Trap Arrays. Micromachines. 2021 Academic Article GET IT
Times cited: 11
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy. Cancer discovery. 2021 Academic Article GET IT
Times cited: 362
Imaging angiogenesis in atherosclerosis in large arteries with ⁶⁸Ga-NODAGA-RGD PET/CT: relationship with clinical atherosclerotic cardiovascular disease. EJNMMI research. 2021 Academic Article GET IT
Times cited: 21
Soluble trivalent engagers redirect cytolytic T cell activity toward tumor endothelial marker 1. Cell reports. Medicine. 2021 Academic Article GET IT
Times cited: 15
VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding. Journal for immunotherapy of cancer. 2021 Academic Article GET IT
Times cited: 42
Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING. Cell reports. 2021 Academic Article GET IT
Times cited: 94
Interpretation of T cell states from single-cell transcriptomics data using reference atlases. Nature communications. 2021 Review GET IT
Times cited: 347
Author Correction: Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer. 2021 GET IT
Times cited: 3
Unsupervised Analysis of Flow Cytometry Data in a Clinical Setting Captures Cell Diversity and Allows Population Discovery. Frontiers in immunology. 2021 Academic Article GET IT
Times cited: 14
Cell therapies in ovarian cancer. Therapeutic advances in medical oncology. 2021 Review GET IT
Times cited: 30
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy. European journal of cancer. 2021 Academic Article GET IT
Times cited: 149
Sensitive Immunopeptidomics by Leveraging Available Large-Scale Multi-HLA Spectral Libraries, Data-Independent Acquisition, and MS/MS Prediction. Molecular & cellular proteomics : MCP. 2021 Academic Article GET IT
Times cited: 67
Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer. NPJ vaccines. 2021 Academic Article GET IT
Times cited: 44
Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer. Science advances. 2021 Academic Article GET IT
Times cited: 252
Azole-Based Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors. Journal of medicinal chemistry. 2021 Academic Article GET IT
Times cited: 15
Prediction of neo-epitope immunogenicity reveals TCR recognition determinants and provides insight into immunoediting. Cell reports. Medicine. 2021 Academic Article GET IT
Times cited: 117
Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression. The Journal of experimental medicine. 2021 Academic Article GET IT
Times cited: 140
Impact of DOTA Conjugation on Pharmacokinetics and Immunoreactivity of [¹⁷⁷Lu]Lu-1C1m-Fc, an Anti TEM-1 Fusion Protein Antibody in a TEM-1 Positive Tumor Mouse Model. Pharmaceutics. 2021 Academic Article GET IT
Times cited: 14
Abscopal effect in a patient with malignant pleural mesothelioma treated with palliative radiotherapy and pembrolizumab. 2021 GET IT
Times cited: 11
Biological evaluation of new TEM1 targeting recombinant antibodies for radioimmunotherapy: In vitro, in vivo and in silico studies. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 2020 Academic Article GET IT
Times cited: 5
Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis. European journal of cancer. 2020 Review GET IT
Times cited: 31
Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment. Cytotherapy. 2020 Academic Article GET IT
Times cited: 16
Disturbed mitochondrial dynamics in CD8⁺ TILs reinforce T cell exhaustion. Nature immunology. 2020 Academic Article GET IT
Times cited: 443
Mineral and Amino Acid Profiling of Different Hematopoietic Populations from the Mouse Bone Marrow. International journal of molecular sciences. 2020 Academic Article GET IT
Times cited: 7
T-cell repertoire analysis and metrics of diversity and clonality. Current opinion in biotechnology. 2020 Review GET IT
Times cited: 147
High versus low dose irradiation for tumor immune reprogramming. Current opinion in biotechnology. 2020 Review GET IT
Times cited: 24
Turning up the heat on non-immunoreactive tumours: opportunities for clinical development. The Lancet. Oncology. 2020 Review GET IT
Times cited: 179
Biogenesis of HLA Ligand Presentation in Immune Cells Upon Activation Reveals Changes in Peptide Length Preference. Frontiers in immunology. 2020 Academic Article GET IT
Times cited: 13
¹⁷⁷Lu radiolabeling and preclinical theranostic study of 1C1m-Fc: an anti-TEM-1 scFv-Fc fusion protein in soft tissue sarcoma. EJNMMI research. 2020 Academic Article GET IT
Times cited: 16
Structural dissimilarity from self drives neoepitope escape from immune tolerance. Nature chemical biology. 2020 Academic Article GET IT
Times cited: 52
Correction to: Preclinical Evaluation and Dosimetry of [¹¹¹In] CHX-DTPA-scFv78-Fc Targeting Endosialin/Tumor Endothelial Marker 1 (TEM1). 2020 GET IT
Guillain-Barré syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes. Journal for immunotherapy of cancer. 2020 Academic Article GET IT
Times cited: 9
Preclinical Evaluation and Dosimetry of [¹¹¹In]CHX-DTPA-scFv78-Fc Targeting Endosialin/Tumor Endothelial Marker 1 (TEM1). Molecular imaging and biology. 2020 Academic Article GET IT
Times cited: 22
Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes. Journal for immunotherapy of cancer. 2020 Academic Article GET IT
Times cited: 25
Cancer and HIV-1 Infection: Patterns of Chronic Antigen Exposure. Frontiers in immunology. 2020 Review GET IT
Times cited: 17
Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal. Frontiers in immunology. 2020 Review GET IT
Times cited: 35
Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer. European journal of cancer. 2020 Academic Article GET IT
Times cited: 42
Multielemental Analysis of Low-Volume Samples Reveals Cancer-Specific Profile in Serum and Sorted Immune Cells. Analytical chemistry. 2020 Academic Article GET IT
Times cited: 10
High-throughput automated organoid culture via stem-cell aggregation in microcavity arrays. Nature biomedical engineering. 2020 Academic Article GET IT
Times cited: 317
Immune Therapy Opportunities in Ovarian Cancer. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2020 Review GET IT
Optimized combinatorial pMHC class II multimer labeling for precision immune monitoring of tumor-specific CD4 T cells in patients. Journal for immunotherapy of cancer. 2020 Academic Article GET IT
Times cited: 7
Cathepsin S Regulates Antigen Processing and T Cell Activity in Non-Hodgkin Lymphoma. Cancer cell. 2020 Academic Article GET IT
Times cited: 86
Author Correction: A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy. 2020 GET IT
Times cited: 3
Neoadjuvant immune-checkpoint blockade in resectable colon cancer. Nature medicine. 2020 Comment GET IT
Times cited: 13
Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes. Nature communications. 2020 Academic Article GET IT
Times cited: 243
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. Journal for immunotherapy of cancer. 2020 Review GET IT
Times cited: 940
All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy. Current opinion in biotechnology. 2020 Review GET IT
Times cited: 44
A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy. Nature biotechnology. 2020 Academic Article GET IT
Times cited: 123
Biotechnologies to tackle the challenge of neoantigen identification. Current opinion in biotechnology. 2020 Review GET IT
Times cited: 25
Measurement of Mitochondrial Mass and Membrane Potential in Hematopoietic Stem Cells and T-cells by Flow Cytometry. Journal of visualized experiments : JoVE. 2019 Academic Article GET IT
Times cited: 3
miR-155 Overexpression in OT-1 CD8⁺ T Cells Improves Anti-Tumor Activity against Low-Affinity Tumor Antigen. Molecular therapy oncolytics. 2019 Academic Article GET IT
Times cited: 20
Mass Spectrometry Based Immunopeptidomics Leads to Robust Predictions of Phosphorylated HLA Class I Ligands. Molecular & cellular proteomics : MCP. 2019 Academic Article GET IT
Times cited: 43
Microfluidic device performing on flow study of serial cell-cell interactions of two cell populations. RSC advances. 2019 Academic Article GET IT
Times cited: 7
Neutrophils suppress tumor-infiltrating T cells in colon cancer via matrix metalloproteinase-mediated activation of TGFβ. EMBO molecular medicine. 2019 Academic Article GET IT
Times cited: 143
Deep Response to Anti-PD-1 Therapy of Metastatic Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumor With CD274/PD-L1 Amplification. JCO precision oncology. 2019 Academic Article GET IT
Times cited: 23
Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Review GET IT
Times cited: 209
Gender medicine and oncology: report and consensus of an ESMO workshop. Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Academic Article GET IT
Times cited: 172
A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma. Journal of translational medicine. 2019 Academic Article GET IT
Times cited: 56
Analysis of Secondary Structure Biases in Naturally Presented HLA-I Ligands. Frontiers in immunology. 2019 Academic Article GET IT
Times cited: 8
Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment. Journal for immunotherapy of cancer. 2019 Academic Article GET IT
Times cited: 105
CD8 Binding of MHC-Peptide Complexes in cis or trans Regulates CD8⁺ T-cell Responses. Journal of molecular biology. 2019 Academic Article GET IT
Times cited: 6
Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes. Nature biotechnology. 2019 Academic Article GET IT
Times cited: 226
Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8⁺ T cells. Journal for immunotherapy of cancer. 2019 Academic Article GET IT
Times cited: 172
Integrating SpyCatcher/SpyTag covalent fusion technology into phage display workflows for rapid antibody discovery. Scientific reports. 2019 Academic Article GET IT
Times cited: 17
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nature reviews. Clinical oncology. 2019 Review GET IT
Times cited: 1855
Immunotherapy in Ovarian Cancer: Are We There Yet?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Review GET IT
Times cited: 16
A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three Patients. Frontiers in immunology. 2019 Academic Article GET IT
Times cited: 71
Rational combinations of immunotherapy with radiotherapy in ovarian cancer. The Lancet. Oncology. 2019 Review GET IT
Times cited: 131
Mass spectrometry driven exploration reveals nuances of neoepitope-driven tumor rejection. JCI insight. 2019 Academic Article GET IT
Times cited: 55
¹⁸F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer. European journal of nuclear medicine and molecular imaging. 2019 Academic Article GET IT
Times cited: 76
Internal radiation dosimetry of a ¹⁵²Tb-labeled antibody in tumor-bearing mice. EJNMMI research. 2019 Academic Article GET IT
Times cited: 21
Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. Cancer cell. 2019 Academic Article GET IT
Times cited: 664
High-throughput identification of human antigen-specific CD8⁺ and CD4⁺ T cells using soluble pMHC multimers. Methods in enzymology. 2019 Review GET IT
Times cited: 5
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function. Frontiers in immunology. 2019 Review GET IT
Times cited: 362
[Side effects of immune checkpoint inhibitors: diagnosis and management]. Revue medicale suisse. 2019 Academic Article GET IT
Times cited: 2
High-throughput Screening of Human Tumor Antigen-specific CD4 T Cells, Including Neoantigen-reactive T Cells. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 15
The clinical application of cancer immunotherapy based on naturally circulating dendritic cells. Journal for immunotherapy of cancer. 2019 Review GET IT
Times cited: 157
Correction: Tumour-reactive T cell subsets in the microenvironment of ovarian cancer. 2019 GET IT
Going Beyond the Sequences: TCR Binding Patterns at the Service of Cancer Detection. Cancer research. 2019 Comment GET IT
Times cited: 4
The NAD-Booster Nicotinamide Riboside Potently Stimulates Hematopoiesis through Increased Mitochondrial Clearance. Cell stem cell. 2019 Academic Article GET IT
Times cited: 180
Tumor Landscapes: β-Catenin Drives Immune Desertification. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Comment GET IT
Times cited: 9
Tumour-reactive T cell subsets in the microenvironment of ovarian cancer. British journal of cancer. 2019 Academic Article GET IT
Times cited: 53
Safety and Tolerability of Adoptive Cell Therapy in Cancer. Drug safety. 2019 Review GET IT
Times cited: 66
[Recent advances and future directions in CAR-T cell therapy in pediatric oncology]. Revue medicale suisse. 2019 Review GET IT
Times cited: 1
Computational KIR copy number discovery reveals interaction between inhibitory receptor burden and survival. Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing. 2019 Academic Article GET IT
Times cited: 2
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. The Lancet. Oncology. 2019 Review GET IT
Times cited: 182
A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy. 2018 GET IT
Times cited: 59
The Length Distribution and Multiple Specificity of Naturally Presented HLA-I Ligands. Journal of immunology (Baltimore, Md. : 1950). 2018 Academic Article GET IT
Times cited: 127
A severe case of neuro-Sjögren's syndrome induced by pembrolizumab. 2018 GET IT
Times cited: 45
Two-Dimensional Label-Free Affinity Analysis of Tumor-Specific CD8 T Cells with a Biomimetic Plasmonic Sensor. ACS sensors. 2018 Academic Article GET IT
Times cited: 26
50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial. International journal of radiation oncology, biology, physics. 2018 Academic Article GET IT
Times cited: 38
Correction to: CART cells are prone to Fas- and DR5-mediated cell death. 2018 GET IT
Times cited: 6
Cancer Immunotherapy: A Simple Guide for Interventional Radiologists of New Therapeutic Approaches. Cardiovascular and interventional radiology. 2018 Review GET IT
Times cited: 5
Estimating the Contribution of Proteasomal Spliced Peptides to the HLA-I Ligandome. Molecular & cellular proteomics : MCP. 2018 Academic Article GET IT
Times cited: 83
Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis. 2018 Review GET IT
Times cited: 542
CART cells are prone to Fas- and DR5-mediated cell death. Journal for immunotherapy of cancer. 2018 Academic Article GET IT
Times cited: 71
Current Opinion and Knowledge on Peritoneal Carcinomatosis: A Survey among a Swiss Oncology Network. Chemotherapy. 2018 Academic Article GET IT
Times cited: 5
Label-Free Optofluidic Nanobiosensor Enables Real-Time Analysis of Single-Cell Cytokine Secretion. Small (Weinheim an der Bergstrasse, Germany). 2018 Academic Article GET IT
Times cited: 97
The C-terminal extension landscape of naturally presented HLA-I ligands. Proceedings of the National Academy of Sciences of the United States of America. 2018 Academic Article GET IT
Times cited: 35
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Science translational medicine. 2018 Academic Article GET IT
Times cited: 387
T cell-induced CSF1 promotes melanoma resistance to PD1 blockade. Science translational medicine. 2018 Academic Article GET IT
Times cited: 258
Immune-related adverse events of immune checkpoint inhibitors and the impact of sex-what we know and what we need to learn. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Letter GET IT
Times cited: 17
Sensitive and frequent identification of high avidity neo-epitope specific CD8 ⁺ T cells in immunotherapy-naive ovarian cancer. Nature communications. 2018 Academic Article GET IT
Times cited: 139
Correction to: Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy. 2018 GET IT
Times cited: 6
Tumour endothelial marker 1/endosialin-mediated targeting of human sarcoma. European journal of cancer. 2018 Academic Article GET IT
Times cited: 30
High-throughput and Sensitive Immunopeptidomics Platform Reveals Profound Interferonγ-Mediated Remodeling of the Human Leukocyte Antigen (HLA) Ligandome. Molecular & cellular proteomics : MCP. 2017 Academic Article GET IT
Times cited: 158
Cancer immunotherapy full speed ahead. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Editorial Article GET IT
Times cited: 9
Mechanisms regulating T-cell infiltration and activity in solid tumors. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 312
'Hotspots' of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization. Frontiers in immunology. 2017 Academic Article GET IT
Times cited: 72
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. Nature communications. 2017 Academic Article GET IT
Times cited: 207
Interrogating open issues in cancer medicine with patient-derived xenografts. 2017 GET IT
Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificity. PLoS computational biology. 2017 Academic Article GET IT
Times cited: 201
The T-Cell Receptor Can Bind to the Peptide-Bound Major Histocompatibility Complex and Uncomplexed β₂-Microglobulin through Distinct Binding Sites. Biochemistry. 2017 Academic Article GET IT
Times cited: 7
Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy. Oncoimmunology. 2017 Academic Article GET IT
Times cited: 57
The ovarian cancer oncobiome. Oncotarget. 2017 Academic Article GET IT
Times cited: 180
In silico and cell-based analyses reveal strong divergence between prediction and observation of T-cell-recognized tumor antigen T-cell epitopes. The Journal of biological chemistry. 2017 Academic Article GET IT
Times cited: 26
A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 84
Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel. Frontiers in immunology. 2017 Review GET IT
Times cited: 71
TIE-2 expressing monocytes in human cancers. Oncoimmunology. 2017 Academic Article GET IT
Times cited: 54
Label-free identification of activated T lymphocytes through tridimensional microsensors on chip. Biosensors & bioelectronics. 2017 Academic Article GET IT
Times cited: 41
Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nature reviews. Cancer. 2017 Review GET IT
Times cited: 604
Identifying biological mechanisms for favorable cancer prognosis using non-hypothesis-driven iterative survival analysis. NPJ systems biology and applications. 2016 Academic Article GET IT
Times cited: 4
Combine and Conquer: Double CTLA-4 and PD-1 Blockade Combined with Whole Tumor Antigen Vaccine Cooperate to Eradicate Tumors. Cancer research. 2016 Academic Article GET IT
Times cited: 6
Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk. Oncoimmunology. 2016 Academic Article GET IT
Times cited: 62
Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 34
Radiotherapy combination opportunities leveraging immunity for the next oncology practice. CA: a cancer journal for clinicians. 2016 Review GET IT
Times cited: 471
1,2,3-Triazoles as inhibitors of indoleamine 2,3-dioxygenase 2 (IDO2). Bioorganic & medicinal chemistry letters. 2016 Academic Article GET IT
Times cited: 39
Neoantigen-based cancer immunotherapy. Annals of translational medicine. 2016 Review GET IT
Times cited: 70
[Not Available]. Revue medicale suisse. 2016 Editorial Article GET IT
[Principles of adoptive cell therapy based on "Tumor Infiltrating Lymphocytes"]. Revue medicale suisse. 2016 Academic Article GET IT
Mass spectrometry-based antigen discovery for cancer immunotherapy. Current opinion in immunology. 2016 Review GET IT
Times cited: 120
The Human Vaccines Project: A roadmap for cancer vaccine development. Science translational medicine. 2016 Review GET IT
Times cited: 160
Opportunities in immunotherapy of ovarian cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2016 Review GET IT
Times cited: 62
TCR-engineered T cells to treat tumors: Seeing but not touching?. Seminars in immunology. 2016 Review GET IT
Times cited: 67
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nature reviews. Cancer. 2015 Review GET IT
Times cited: 944
Targeting Programmed Cell Death 1 in Ovarian Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Editorial Article GET IT
Times cited: 19
Ovarian cancer chemokines may not be a significant barrier during whole tumor antigen dendritic-cell vaccine and adoptive T-cell immunotherapy. Oncoimmunology. 2015 Academic Article GET IT
Times cited: 5
Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers. Cancer cell. 2015 Academic Article GET IT
Times cited: 579
Erratum to: Multifunctional mitoxantrone-conjugated magnetic nanosystem for targeted therapy of folate receptor-overexpressing malignant cells. 2015 GET IT
Times cited: 3
Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era. Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Review GET IT
Times cited: 45
Overexpression of GPC6 and TMEM132D in Early Stage Ovarian Cancer Correlates with CD8+ T-Lymphocyte Infiltration and Increased Patient Survival. BioMed research international. 2015 Academic Article GET IT
Times cited: 23
TIE-2-expressing monocytes are lymphangiogenic and associate specifically with lymphatics of human breast cancer. Oncoimmunology. 2015 Academic Article GET IT
Times cited: 45
Personalized approaches to active immunotherapy in cancer. Biochimica et biophysica acta. 2015 Review GET IT
Times cited: 52
High-throughput monitoring of human tumor-specific T-cell responses with large peptide pools. Oncoimmunology. 2015 Academic Article GET IT
Times cited: 23
Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?. Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Review GET IT
Times cited: 245
Whole Tumor Antigen Vaccines: Where Are We?. Vaccines. 2015 Review GET IT
Times cited: 235
Multifunctional mitoxantrone-conjugated magnetic nanosystem for targeted therapy of folate receptor-overexpressing malignant cells. Journal of nanobiotechnology. 2015 Academic Article GET IT
Times cited: 79
Angiogenic activity of breast cancer patients' monocytes reverted by combined use of systems modeling and experimental approaches. PLoS computational biology. 2015 Academic Article GET IT
Times cited: 20
Tumor-infiltrating lymphocytes in triple-negative breast cancer: a biomarker for use beyond prognosis?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Letter GET IT
Times cited: 9
An ultra-sensitive impedimetric immunosensor for detection of the serum oncomarker CA-125 in ovarian cancer patients. Nanoscale. 2015 Academic Article GET IT
Times cited: 141
Consensus nomenclature for CD8⁺ T cell phenotypes in cancer. Oncoimmunology. 2015 Academic Article GET IT
Times cited: 128
The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 56
Targeting the tumor vasculature to enhance T cell activity. Current opinion in immunology. 2015 Review GET IT
Times cited: 289
Potential approaches for more successful dendritic cell-based immunotherapy. Expert opinion on biological therapy. 2015 Review GET IT
Times cited: 29
Phage antibody display libraries: a powerful antibody discovery platform for immunotherapy. Critical reviews in biotechnology. 2014 Review GET IT
Times cited: 92
T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression. Cancer immunology research. 2014 Academic Article GET IT
Times cited: 95
Development, optimization, and validation of novel anti-TEM1/CD248 affinity agent for optical imaging in cancer. Oncotarget. 2014 Academic Article GET IT
Times cited: 15
Bone marrow-derived cells are implicated as a source of lymphatic endothelial progenitors in human breast cancer. Oncoimmunology. 2014 Academic Article GET IT
Times cited: 23
Overexpression of SMARCE1 is associated with CD8+ T-cell infiltration in early stage ovarian cancer. The international journal of biochemistry & cell biology. 2014 Academic Article GET IT
Times cited: 17
[Together, towards precise oncology!]. Revue medicale suisse. 2014 Editorial Article GET IT
[Genomics medicine and oncology]. Praxis. 2014 Academic Article GET IT
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nature medicine. 2014 Academic Article GET IT
Times cited: 864
T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Cancer discovery. 2014 Academic Article GET IT
Times cited: 391
Shikonin-loaded antibody-armed nanoparticles for targeted therapy of ovarian cancer. International journal of nanomedicine. 2014 Academic Article GET IT
Times cited: 84
Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature. The Journal of clinical investigation. 2014 Academic Article GET IT
Times cited: 64
Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model. Cancer biology & therapy. 2014 Academic Article GET IT
Times cited: 22
Development of 124I immuno-PET targeting tumor vascular TEM1/endosialin. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2014 Academic Article GET IT
Times cited: 31
Cancer immunotherapy: hype or ripe? [corrected]. European journal of immunology. 2014 Article GET IT
Times cited: 2
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--response. Cancer research. 2014 Letter GET IT
Times cited: 45
A new twist on radiation oncology: low-dose irradiation elicits immunostimulatory macrophages that unlock barriers to tumor immunotherapy. Cancer cell. 2013 Comment GET IT
Times cited: 50
CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 269
Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer research. 2013 Academic Article GET IT
Times cited: 250
Predicting time to ovarian carcinoma recurrence using protein markers. The Journal of clinical investigation. 2013 Academic Article GET IT
Times cited: 55
Replenish the source within: Rescuing tumor-infiltrating lymphocytes by double checkpoint blockade. Oncoimmunology. 2013 Academic Article GET IT
Chemoimmunotherapy using pegylated liposomal Doxorubicin and interleukin-18 in recurrent ovarian cancer: a phase I dose-escalation study. Cancer immunology research. 2013 Academic Article GET IT
Times cited: 47
Deciphering and reversing tumor immune suppression. Immunity. 2013 Review GET IT
Times cited: 532
A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 205
A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. Journal of translational medicine. 2013 Academic Article GET IT
Times cited: 68
Targeted delivery of antibody-based therapeutic and imaging agents to CNS tumors: crossing the blood-brain barrier divide. Expert opinion on drug delivery. 2013 Review GET IT
Times cited: 102
TIE-2 and VEGFR kinase activities drive immunosuppressive function of TIE-2-expressing monocytes in human breast tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 36
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer research. 2013 Academic Article GET IT
Times cited: 606
TIE2-expressing monocytes: a novel cellular biomarker for hepatocellular carcinoma?. Hepatology (Baltimore, Md.). 2013 Editorial Article GET IT
Times cited: 6
Tamoxifen loaded folic acid armed PEGylated magnetic nanoparticles for targeted imaging and therapy of cancer. Colloids and surfaces. B, Biointerfaces. 2013 Academic Article GET IT
Times cited: 108
Specific targeting of cancer cells by multifunctional mitoxantrone-conjugated magnetic nanoparticles. Journal of drug targeting. 2013 Academic Article GET IT
Times cited: 60
Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology. 2013 Academic Article GET IT
Times cited: 140
Targeting cytokines: production and characterization of anti-TNF-α scFvs by phage display technology. Current pharmaceutical design. 2013 Academic Article GET IT
Times cited: 24
Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels. PloS one. 2012 Academic Article GET IT
Times cited: 64
Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. Neoplasia (New York, N.Y.). 2012 Academic Article GET IT
Times cited: 124
A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. Journal of translational medicine. 2012 Academic Article GET IT
Times cited: 117
Conference scene: Immune signatures in the tumor and beyond. Immunotherapy. 2012 Article GET IT
Know thy enemy: Why are tumor-infiltrating regulatory T cells so deleterious?. Oncoimmunology. 2012 Academic Article GET IT
Times cited: 16
T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer research. 2012 Review GET IT
Times cited: 704
miRNAs in human cancer. Methods in molecular biology (Clifton, N.J.). 2012 Academic Article GET IT
Times cited: 67
Cancer immunotherapy comes of age. Nature. 2011 Review GET IT
Times cited: 3405
Day-4 myeloid dendritic cells pulsed with whole tumor lysate are highly immunogenic and elicit potent anti-tumor responses. PloS one. 2011 Academic Article GET IT
Times cited: 50
Defining the critical hurdles in cancer immunotherapy. Journal of translational medicine. 2011 Editorial Article GET IT
Times cited: 145
High-throughput biomarker segmentation on ovarian cancer tissue microarrays via hierarchical normalized cuts. IEEE transactions on bio-medical engineering. 2011 Academic Article GET IT
Times cited: 27
Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. Molecular therapy : the journal of the American Society of Gene Therapy. 2011 Academic Article GET IT
Times cited: 165
A xenograft mouse model coupled with in-depth plasma proteome analysis facilitates identification of novel serum biomarkers for human ovarian cancer. Journal of proteome research. 2011 Academic Article GET IT
Times cited: 53
Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate. Journal of translational medicine. 2011 Academic Article GET IT
Times cited: 29
A combined array-based comparative genomic hybridization and functional library screening approach identifies mir-30d as an oncomir in cancer. Cancer research. 2011 Academic Article GET IT
Times cited: 50
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecologic oncology. 2011 Review GET IT
Times cited: 556
Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer immunology, immunotherapy : CII. 2011 Academic Article GET IT
Times cited: 107
Rethinking ovarian cancer: recommendations for improving outcomes. Nature reviews. Cancer. 2011 Guideline GET IT
Times cited: 1082
The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nature reviews. Immunology. 2011 Academic Article GET IT
Times cited: 428
Tissue-based immune monitoring I: tumor core needle biopsies allow in-depth interrogation of the tumor microenvironment. Cancer biology & therapy. 2011 Academic Article GET IT
Times cited: 11
Tissue-based immune monitoring II: multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinoma. Cancer biology & therapy. 2011 Academic Article GET IT
Times cited: 22
Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes. Journal of translational medicine. 2011 Academic Article GET IT
Times cited: 57
Novel surface targets and serum biomarkers from the ovarian cancer vasculature. Cancer biology & therapy. 2011 Academic Article GET IT
Times cited: 35
Clinical translation section: accelerating the pace from bench to bedside. Journal of translational medicine. 2011 Editorial Article GET IT
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature. 2011 Academic Article GET IT
Times cited: 1199
Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy. Journal of translational medicine. 2011 Academic Article GET IT
Times cited: 44
Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome. Genes, chromosomes & cancer. 2011 Academic Article GET IT
Times cited: 104
In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer research. 2011 Academic Article GET IT
Times cited: 254
Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer. PloS one. 2011 Academic Article GET IT
Times cited: 30
Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance. Cancer metastasis reviews. 2011 Review GET IT
Times cited: 50
Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. International reviews of immunology. 2011 Review GET IT
Times cited: 101
Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin. Current topics in microbiology and immunology. 2011 Review GET IT
Times cited: 90
Clinical predictors of bevacizumab-associated gastrointestinal perforation. Gynecologic oncology. 2010 Academic Article GET IT
Times cited: 35
Immunotherapy for ovarian cancer: what's next?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Review GET IT
Times cited: 122
Double-negative feedback loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer stem cells. Cancer research. 2010 Academic Article GET IT
Times cited: 149
Identification of microRNAs regulating reprogramming factor LIN28 in embryonic stem cells and cancer cells. The Journal of biological chemistry. 2010 Academic Article GET IT
Times cited: 148
Rapid isolation of high-affinity human antibodies against the tumor vascular marker Endosialin/TEM1, using a paired yeast-display/secretory scFv library platform. Journal of immunological methods. 2010 Academic Article GET IT
Times cited: 49
Cancer and inflammation: promise for biologic therapy. Journal of immunotherapy (Hagerstown, Md. : 1997). 2010 Review GET IT
Times cited: 282
Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PloS one. 2010 Academic Article GET IT
Times cited: 370
Whole tumor antigen vaccines. Seminars in immunology. 2010 Review GET IT
Times cited: 225
Tumor vascular biomarkers: new opportunities for cancer diagnostics. Cancer biomarkers : section A of Disease markers. 2010 Review GET IT
Times cited: 12
Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18. Journal of translational medicine. 2009 Academic Article GET IT
Times cited: 38
The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade. Gynecologic oncology. 2009 Review GET IT
Times cited: 31
Therapeutic microRNA strategies in human cancer. The AAPS journal. 2009 Review GET IT
Times cited: 178
KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer. Nature cell biology. 2009 Academic Article GET IT
Times cited: 166
Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer. 2009 Academic Article GET IT
Times cited: 113
Endothelin B receptor, a new target in cancer immune therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Review GET IT
Times cited: 101
Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. Journal of translational medicine. 2009 Academic Article GET IT
Times cited: 58
Beyond CA125: the coming of age of ovarian cancer biomarkers. Are we there yet?. Biomarkers in medicine. 2009 Academic Article GET IT
Times cited: 40
Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 2009 Academic Article GET IT
Times cited: 700
In vivo dendritic cell tracking using fluorescence lifetime imaging and near-infrared-emissive polymersomes. Molecular imaging and biology. 2009 Academic Article GET IT
Times cited: 41
Expression of activated PIK3CA in ovarian surface epithelium results in hyperplasia but not tumor formation. PloS one. 2009 Academic Article GET IT
Times cited: 26
Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines. Frontiers in bioscience (Landmark edition). 2009 Review GET IT
Times cited: 63
Expression profile of microRNA in epithelial cancer: diagnosis, classification and prediction. Expert opinion on medical diagnostics. 2009 Academic Article GET IT
Times cited: 4
Hierarchical normalized cuts: unsupervised segmentation of vascular biomarkers from ovarian cancer tissue microarrays. Medical image computing and computer-assisted intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention. 2009 Academic Article GET IT
Times cited: 15
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". Journal of translational medicine. 2008 Editorial Article GET IT
Times cited: 49
MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer research. 2008 Academic Article GET IT
Times cited: 349
Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2008 Academic Article GET IT
Times cited: 242
Ovarian cancer early detection claims are biased. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Letter GET IT
Times cited: 31
Modulation of the antitumor immune response by complement. Nature immunology. 2008 Academic Article GET IT
Times cited: 667
Distinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cells. PloS one. 2008 Academic Article GET IT
Times cited: 57
Mechanisms of microRNA deregulation in human cancer. Cell cycle (Georgetown, Tex.). 2008 Review GET IT
Times cited: 294
Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation. Cancer biology & therapy. 2008 Academic Article GET IT
Times cited: 76
Ultraconserved elements: genomics, function and disease. RNA biology. 2008 Review GET IT
Times cited: 39
Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. 2008 Academic Article GET IT
Times cited: 485
Whole tumor antigen vaccination using dendritic cells: comparison of RNA electroporation and pulsing with UV-irradiated tumor cells. Journal of translational medicine. 2008 Academic Article GET IT
Times cited: 65
Transcriptional regulation of PIK3CA oncogene by NF-kappaB in ovarian cancer microenvironment. PloS one. 2008 Academic Article GET IT
Times cited: 33
MicroRNA epigenetic alterations in human cancer: one step forward in diagnosis and treatment. International journal of cancer. 2008 Review GET IT
Times cited: 95
Varying coefficient model with unknown within-subject covariance for analysis of tumor growth curves. Biometrics. 2008 Academic Article GET IT
Times cited: 15
Immunotherapy opportunities in ovarian cancer. Expert review of anticancer therapy. 2008 Review GET IT
Times cited: 63
The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nature cell biology. 2008 Academic Article GET IT
Times cited: 913
Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer. Journal of translational medicine. 2008 Academic Article GET IT
Times cited: 19
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nature medicine. 2008 Academic Article GET IT
Times cited: 493
Biological therapy with oncolytic herpesvirus. Advances in experimental medicine and biology. 2008 Review GET IT
Times cited: 7
Inhibitory B7 family members in human ovarian carcinoma. Advances in experimental medicine and biology. 2008 Review GET IT
Times cited: 5
MicroRNA in human cancer: one step forward in diagnosis and treatment. Advances in experimental medicine and biology. 2008 Review GET IT
Times cited: 8
Regulatory T cells: a new frontier in cancer immunotherapy. Advances in experimental medicine and biology. 2008 Review GET IT
Times cited: 25
Role of vascular leukocytes in ovarian cancer neovascularization. Advances in experimental medicine and biology. 2008 Review GET IT
Times cited: 12
miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer biology & therapy. 2007 Academic Article GET IT
Times cited: 328
Integrative genomic analysis of phosphatidylinositol 3'-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 113
Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer research. 2007 Academic Article GET IT
Times cited: 290
Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics. Journal of immunotherapy (Hagerstown, Md. : 1997). 2007 Review GET IT
Times cited: 2
miRNA genetic alterations in human cancers. Expert opinion on biological therapy. 2007 Review GET IT
Times cited: 49
Luteogenic hormones act through a vascular endothelial growth factor-dependent mechanism to up-regulate alpha 5 beta 1 and alpha v beta 3 integrins, promoting the migration and survival of human luteinized granulosa cells. The American journal of pathology. 2007 Academic Article GET IT
Times cited: 21
Cancer cell lines as genetic models of their parent histology: analyses based on array comparative genomic hybridization. Cancer research. 2007 Review GET IT
Times cited: 67
Tumor vascular proteins as biomarkers in ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 178
Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer research. 2007 Academic Article GET IT
Times cited: 250
Immune prognostic factors in ovarian cancer: lessons from translational research. Disease markers. 2007 Review GET IT
Times cited: 4
Vascular leukocytes: a population with angiogenic and immunossuppressive properties highly represented in ovarian cancer. Advances in experimental medicine and biology. 2007 Review GET IT
Times cited: 20
Interferon beta adenoviral gene therapy in a patient with ovarian cancer. 2006 GET IT
Times cited: 27
MicroRNAs: a new insight into cancer genome. Cell cycle (Georgetown, Tex.). 2006 Review GET IT
Times cited: 29
Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice. Gene therapy. 2006 Academic Article GET IT
Times cited: 44
Direct vaccination with tumor cells killed with ICP4-deficient HSVd120 elicits effective antitumor immunity. Cancer biology & therapy. 2006 Academic Article GET IT
Times cited: 18
Involvement of endothelial CD44 during in vivo angiogenesis. The American journal of pathology. 2006 Academic Article GET IT
Times cited: 128
Use of immuno-LCM to identify the in situ expression profile of cellular constituents of the tumor microenvironment. Cancer biology & therapy. 2006 Academic Article GET IT
Times cited: 56
microRNAs exhibit high frequency genomic alterations in human cancer. Proceedings of the National Academy of Sciences of the United States of America. 2006 Academic Article GET IT
Times cited: 966
Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma. Cancer research. 2006 Academic Article GET IT
Times cited: 117
Preparation of apoptotic tumor cells with replication-incompetent HSV augments the efficacy of dendritic cell vaccines. Cancer gene therapy. 2006 Academic Article GET IT
Times cited: 20
Laser-capture microdissection. Nature protocols. 2006 Academic Article GET IT
Times cited: 617
Immunotherapy for gynaecological malignancies. Expert opinion on biological therapy. 2005 Review GET IT
Times cited: 32
Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma. Human gene therapy. 2005 Academic Article GET IT
Times cited: 73
HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. Molecular therapy : the journal of the American Society of Gene Therapy. 2005 Academic Article GET IT
Times cited: 113
The role of dendritic cell precursors in tumour vasculogenesis. British journal of cancer. 2005 Review GET IT
Times cited: 96
The fibronectin receptor alpha5 integrin subunit is upregulated by cell-cell adhesion via a cyclic AMP-dependent mechanism: implications for human trophoblast migration. American journal of obstetrics and gynecology. 2005 Academic Article GET IT
Times cited: 15
Transcriptional coactivator Drosophila eyes absent homologue 2 is up-regulated in epithelial ovarian cancer and promotes tumor growth. Cancer research. 2005 Academic Article GET IT
Times cited: 95
Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health. Journal of immunotherapy (Hagerstown, Md. : 1997). 2005 Article GET IT
Times cited: 34
RNA interference: a potential strategy for isoform-specific phosphatidylinositol 3-kinase targeted therapy in ovarian cancer. Cancer biology & therapy. 2004 Academic Article GET IT
Times cited: 17
Vascular leukocytes contribute to tumor vascularization. Blood. 2004 Academic Article GET IT
Times cited: 167
Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nature medicine. 2004 Academic Article GET IT
Times cited: 423
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature medicine. 2004 Academic Article GET IT
Times cited: 4561
Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28- antitumor T cells. Cancer research. 2004 Academic Article GET IT
Times cited: 67
Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics. 2003 Academic Article GET IT
Times cited: 204
The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma. Cancer research. 2003 Academic Article GET IT
Times cited: 68
Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer research. 2003 Academic Article GET IT
Times cited: 252
Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. Biochemical and biophysical research communications. 2003 Academic Article GET IT
Times cited: 122
Intraperitoneal oncolytic and tumor vaccination therapy with replication-competent recombinant virus: the herpes paradigm. Current gene therapy. 2003 Review GET IT
Times cited: 13
TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Academic Article GET IT
Times cited: 95
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. The New England journal of medicine. 2003 Academic Article GET IT
Times cited: 3004
Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Academic Article GET IT
Times cited: 58
Letal, A tumor-associated NKG2D immunoreceptor ligand, induces activation and expansion of effector immune cells. Cancer biology & therapy. 2003 Academic Article GET IT
Times cited: 56
Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. The American journal of pathology. 2002 Academic Article GET IT
Times cited: 128
Prophylactic oophorectomy. Best practice & research. Clinical obstetrics & gynaecology. 2002 Review GET IT
Times cited: 14
Different effects of glucose starvation on expression and stability of VEGF mRNA isoforms in murine ovarian cancer cells. Biochemical and biophysical research communications. 2002 Academic Article GET IT
Times cited: 64
Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation. Human gene therapy. 2002 Academic Article GET IT
Times cited: 67
Expression of Wilms' tumor suppressor gene (WT1) in human endometrium: regulation through decidual differentiation. The Journal of clinical endocrinology and metabolism. 2001 Academic Article GET IT
Times cited: 30
Corticotropin-releasing hormone promotes blastocyst implantation and early maternal tolerance. Nature immunology. 2001 Academic Article GET IT
Times cited: 216
Gene therapy for ovarian cancer. Oncology (Williston Park, N.Y.). 2001 Review GET IT
Times cited: 10
Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer research. 2001 Academic Article GET IT
Times cited: 1054
Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000 Academic Article GET IT
Times cited: 66
Early ovarian cancer. Current treatment options in oncology. 2000 Review GET IT
Times cited: 7
Inhibitory G protein alpha subunit (Gi alpha) expression and localization during human trophoblast differentiation. European journal of obstetrics, gynecology, and reproductive biology. 2000 Academic Article GET IT
Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy. Cancer gene therapy. 2000 Academic Article GET IT
Times cited: 64
Follicular atresia and luteolysis. Evidence of a role for N-cadherin. Annals of the New York Academy of Sciences. 2000 Review GET IT
Times cited: 22
Progesterone is an autocrine/paracrine regulator of human granulosa cell survival in vitro. Annals of the New York Academy of Sciences. 2000 Academic Article GET IT
Times cited: 68
Prolonged remission of recurrent, metastatic placental site trophoblastic tumor after chemotherapy. 2000 GET IT
Times cited: 28
Regulated expression and potential roles of p53 and Wilms' tumor suppressor gene (WT1) during follicular development in the human ovary. The Journal of clinical endocrinology and metabolism. 2000 Academic Article GET IT
Times cited: 52
Oncolytic therapy using a mutant type-1 herpes simplex virus and the role of the immune system. The Annals of thoracic surgery. 1999 Academic Article GET IT
Times cited: 17
Complete hydatidiform mole. A disease with a changing profile. The Journal of reproductive medicine. 1999 Academic Article GET IT
Times cited: 69
Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 1999 Academic Article GET IT
Times cited: 111
N-cadherin-mediated human granulosa cell adhesion prevents apoptosis: a role in follicular atresia and luteolysis?. The American journal of pathology. 1999 Academic Article GET IT
Times cited: 94
Chemotherapy resistance in ovarian cancer: new molecular perspectives. Obstetrics and gynecology. 1998 Review GET IT
Times cited: 76
Macrophage-colony stimulating factor (M-CSF) regulates the expression of fibronectin and its alpha5 integrin receptor in human trophoblasts. Endocrinology. 1998 Academic Article GET IT
Times cited: 24
Platelet-endothelial cell adhesion molecule-1 is expressed by a subpopulation of human trophoblasts: a possible mechanism for trophoblast-endothelial interaction during haemochorial placentation. Molecular human reproduction. 1998 Academic Article GET IT
Times cited: 28
Integrins, endometrial maturation, & human embryo implantation. Seminars in reproductive endocrinology. 1998 Review GET IT
Times cited: 22
Potential roles for the low density lipoprotein receptor family of proteins in implantation and placentation. Annals of the New York Academy of Sciences. 1994 Review GET IT
Times cited: 9
Human immunodeficiency virus type 1 causes productive infection of macrophages in primary placental cell cultures. The Journal of infectious diseases. 1994 Academic Article GET IT
Times cited: 53
Expression of alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein and the 39-kd receptor-associated protein in human trophoblasts. The American journal of pathology. 1994 Academic Article GET IT
Times cited: 37
Differentiation-dependent expression of the BCL-2 proto-oncogene in the human trophoblast lineage. Journal of the Society for Gynecologic Investigation. 1994 Academic Article GET IT
Times cited: 67
Effects of growth hormone administration in addition to gonadotrophins in normally ovulating women and polycystic ovary syndrome (PCO) patients. Human reproduction (Oxford, England). 1992 Academic Article GET IT
Times cited: 23
Regulated expression of the trophoblast alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Differentiation and cAMP modulate protein and mRNA levels. The Journal of biological chemistry. 1992 Academic Article GET IT
Times cited: 55
Efficacy of hormone replacement therapy in postmenopausal women with oral discomfort. Oral surgery, oral medicine, and oral pathology. 1992 Academic Article GET IT
Times cited: 145
Sperm retrieval for direct intraperitoneal insemination in a diabetic with retrograde ejaculation. A case report. 1992 GET IT
Times cited: 5
Follicular fluid steroid and epidermal growth factor content, and in vitro estrogen release by granulosa-luteal cells from patients with polycystic ovaries in an IVF/ET program. European journal of obstetrics, gynecology, and reproductive biology. 1991 Academic Article GET IT
Times cited: 26
Clinical use of growth hormone-releasing factor for induction of superovulation. Human reproduction (Oxford, England). 1991 Academic Article GET IT
Times cited: 20
Follicular fluid lipoproteins in preovulatory period and their relationship with follicular maturation and progesterone production by human granulosa-luteal cells in vivo and in vitro. Journal of endocrinological investigation. 1991 Academic Article GET IT
Times cited: 37
Pregnancy following regression of uterine submucosal leiomyoma with GnRH therapy; a case report. 1991 GET IT
Times cited: 4
Doppler velocimetry in prolonged pregnancy. Obstetrics and gynecology. 1991 Academic Article GET IT
Times cited: 27
Involvement of placental neurohormones in human parturition. Annals of the New York Academy of Sciences. 1991 Review GET IT
Times cited: 23
Neuroendocrine mechanisms regulating placental hormone production. Contributions to gynecology and obstetrics. 1991 Review GET IT
Times cited: 7
Corticotropin-releasing factor and parturition: plasma and amniotic fluid levels and placental binding sites. Obstetrics and gynecology. 1990 Academic Article GET IT
Times cited: 72
Pregnancy following combined growth hormone--pulsatile GnRH treatment in a patient with hypothalamic amenorrhoea. 1990 GET IT
Times cited: 16
Progestins modulate the action of estrogen on gonadotropin-releasing hormone, luteinizing hormone and prolactin in the rat. Gynecologic and obstetric investigation. 1990 Academic Article GET IT
Times cited: 13
Plasma and amniotic fluid immunoreactive neuropeptide-Y level changes during pregnancy, labor, and at parturition. The Journal of clinical endocrinology and metabolism. 1989 Academic Article GET IT
Times cited: 38
Ovarian response to combined growth hormone-gonadotropin treatment in patients resistant to induction of superovulation. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 1989 Academic Article GET IT
Times cited: 61
[Noradrenaline and interleukin-1 stimulate CRF secretion from human placental cells in culture]. Medicina (Florence, Italy). 1988 Academic Article GET IT
Times cited: 5

more ...

less ...

Background

education and training

Ph.D., University of Patras Faculty of Medicine (Greece) 1990
M.D., University of Modena Faculty of Medicine (Italy) 1987

Contact

full name

George Coukos

primary email

gec4008@med.cornell.edu

VIVO Weill Cornell Medical College

George Coukos Professor of Immunology in Medicine (Pending Appointment at Rank)

Publications

selected publications

Background

education and training

Contact

full name

primary email